test

Otsuka is dedicated to improving human health worldwide

Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: Otsuka-people creating new products for better health worldwide. Otsuka researches, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for the treatment of diseases and nutraceutical products for the maintenance of everyday health.

In pharmaceuticals, Otsuka is a leading firm in the challenging area of mental health and also has research programs for several under-addressed diseases including tuberculosis, a significant global public health issue. These commitments illustrate more powerfully than words how Otsuka is a “big venture” company at heart, applying a youthful spirit of creativity in everything it does.

Otsuka Pharmaceutical Co., Ltd. is a wholly owned subsidiary of Otsuka Holdings Co., Ltd., the holding company for the Otsuka Group. The chairman Ichiro Otsuka is the third generation of Otsuka family members to lead the business, whose origins date from 1921. The Otsuka Group employs approximately 42,000 people globally and its products are available in more than 80 countries worldwide. Consolidated sales were approximately USD 13 billion for fiscal year 2012 (4/1/2012-3/31/2013).

Otsuka Canada Pharmaceutical Inc. (OCPI) is an innovative, fast-growing health care company, (owned and controlled by Otsuka America Pharmaceutical, Inc. (OAPI), one of the Otsuka Group of Companies) that commercializes Otsuka medicines in Canada, with a focus on and commitment to neuroscience, cardiovascular, oncology and nephrology. OCPI is dedicated to improving patients’ health and the quality of human life. OCPI is part of the Otsuka Group, and was established in 2010, with headquarters in Saint-Laurent, Quebec.


JINARC is a trademark of Otsuka Pharmaceutical Co., Ltd., used under licence by Otsuka Canada Pharmaceutical Inc.
© 2015 Otsuka Canada Pharmaceutical Inc. All rights reserved.